|
Volumn 16, Issue 12, 2000, Pages 1113-1121
|
Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: Week 24 results of a randomized controlled trial - PACTG 377
a b c d b e f g h i j k l m n o p |
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIRETROVIRUS AGENT;
DIDANOSINE;
LAMIVUDINE;
NELFINAVIR;
NEVIRAPINE;
NUCLEOSIDE ANALOG;
PROTEINASE INHIBITOR;
RITONAVIR;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
STAVUDINE;
VIRUS RNA;
ZIDOVUDINE;
ADOLESCENT;
ARTICLE;
CHILD;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DESQUAMATION;
DRUG SAFETY;
DRUG TOLERABILITY;
FEMALE;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
INFANT;
LYMPHOCYTE COUNT;
MAJOR CLINICAL STUDY;
MALE;
MULTICENTER STUDY;
NAUSEA;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
RASH;
TREATMENT OUTCOME;
VOMITING;
ANTI-HIV AGENTS;
CHILD;
CHILD, PRESCHOOL;
CONTINENTAL POPULATION GROUPS;
DRUG THERAPY, COMBINATION;
ETHNIC GROUPS;
FEMALE;
HIV INFECTIONS;
HUMANS;
INFANT;
MALE;
NELFINAVIR;
NEVIRAPINE;
PUERTO RICO;
REVERSE TRANSCRIPTASE INHIBITORS;
RITONAVIR;
RNA, VIRAL;
STAVUDINE;
TIME FACTORS;
UNITED STATES;
VIRAL LOAD;
|
EID: 0034632922
PISSN: 08892229
EISSN: None
Source Type: Journal
DOI: 10.1089/088922200414956 Document Type: Article |
Times cited : (70)
|
References (14)
|